Project Grant SB1CA301959
Award Date 9/1/25
Completion Date 8/31/26
Dollars Obligated $250K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St Paul, MN 55116, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine provides $696,569.00 in funding to advance research on a novel therapy for lung cancer. The research aims to characterize the role of the protein lipocalin 2 (LCN2) in the tumor microenvironment and develop antibody-based therapeutics that interfere with LCN2 function, both as monotherapy and in combination with immune checkpoint blockade. This 5-year...
- This $375,134 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel approach for reducing the off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize an innate immune response that can be leveraged to limit nanoparticle deposition in healthy tissues, thereby enhancing delivery to tumors and improving the efficacy of chemotherapy. The 5-year project, starting on March 1, 2025,...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $2,253,869 to Celdara Medical, LLC to develop CM-HZ01, a novel non-alpha-IL2 therapeutic for the treatment of metastatic melanoma. The funding supports advancing CM-HZ01 to the Investigational New Drug (IND) application stage, with the goal of providing a best-in-class immunotherapy for patients with limited effective treatment options for this deadly form of skin cancer. The project...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $399,998 to Darwin Biosciences, Inc. to develop a low-cost, handheld, and non-invasive lung cancer screening device for use in low-resource settings. The device will incorporate sample collection, nucleic acid biomarker detection via isothermal recombinase polymerase amplification, and a visual readout on lateral flow strips. This work builds on Darwin Biosciences' prior...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $1,233,778 Project Grant to Matrisome Bio, Inc. to develop an extracellular matrix-targeted theranostic radiopharmaceutical for treating metastatic lung cancer. The funding will support research and development efforts to create molecularly targeted drugs using nanobodies that specifically bind to disease-associated extracellular matrix proteins in lung tumors and metastases. This novel approach aims to...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $186,000.00 to The Institute For Cancer Research (ICR) to conduct pilot studies on a new tumor-targeted AURKA (Aurora-A Kinase) inhibitor called NN-01-195. The goal is to investigate the feasibility and potential of this novel chimeric compound, which fuses an HSP90 inhibitor with an AURKA inhibitor, as a cancer treatment approach. The proposed research aims to evaluate the...
- This $658,743 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Kaiser Foundation Hospitals aims to develop and validate prediction models for trajectories of function, cognition, and quality of life among adults aged 65 and older with advanced non-small cell lung cancer during up to 6 months of chemotherapy and/or immunotherapy. The 5-year project builds on an ongoing observational cohort study of 130 older adults with advanced lung...
- The National Cancer Institute awarded a $452,540 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Sloan-Kettering Institute for Cancer Research. The grant funds a 2-year project to investigate the use of electronic nose technology to predict and assess patient response to induction therapy and identify recurrence after curative-intent treatment for non-small cell lung cancer. The project aims to develop more accurate methods to evaluate therapy response and detect...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $703,410.00 to New York University School of Medicine to conduct research on the adeno-to-squamous transition in non-small cell lung cancer. The research aims to identify chromatin regulators that drive this cellular adaptation, which enables resistance to targeted KRAS inhibitor therapy. The award began on January 16, 2025 and is scheduled to run through December 31, 2029....
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) is supporting a research effort led by The Trustees of Columbia University in the City of New York to develop novel inhalable extracellular vesicles (exosomes) for enhanced delivery of interleukin-12 (IL12) to treat lung cancer. The $128,228 award, spanning July 1, 2025 to June 30, 2027, aims to engineer exosome-based RNA delivery platforms that can achieve high mRNA encapsulation, scalability,...